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to RN. This has also translated into a reduced risk of all cause 
mortality in large population series receiving PN as compared 
to RN, as a result of a lower rate of cardiovascular events 
potentially driven by CKD. Backed by these data, current 
guidelines (NCCN 2015, EAU 2014 and AUA 2009) make strong 
recommendations for PN in all T1a (up to 4 cm) and 
whenever feasible in T1b (4-7 cm) kidney cancers. The 
recommendation becomes imperative in patients with 
baseline CKD, bilateral tumours or tumour in a solitary 
kidney. Surprisingly, the only level I evidence available from 
a European RCT could not prove equivalence between PN and 
RN. While the trial did not meet accrual goals (541 out of 
1300 patients required), overall survival (the primary study 
end point) at 9.3 years of follow up was eventually better in 
the RN arm in spite of a better preserved renal function in 
the PN arm. Notably more cardiovascular events were 
observed in the PN group! All these observation taken 
together suggest that the survival advantage of PN over RN 
observed in large retrospective series or metanalyses is likely 
the effect of unaccountable selection biases in favour of PN 
(healthier patients more likely to be treated with PN). The 
beneficial effect of PN on kidney function is out of question, 
yet its clinical relevancy (= reduced risk of non cancer 
related morbidity) is restricted to patients with baseline CKD. 
Up to 30% of patients with SRM have some degree of baseline 
CKD and hence would require a PN that must be performed 
with surgical skill in order to optimize both oncological 
efficacy (negative surgical margin) and kidney function 
preservation (keep ischemia time < 25 minutes or even 
lower). The currently available surgical techniques (open, 
laparoscopic and robotic assisted) have all proved effective 
to accomplish a PN matching the criteria for both oncological 
and functional efficacy.  
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Renal-cellcarcinoma (RCC) is considered to be a 
radioresistant tumour, but this dogma iswrong and based on 
traditional radiation schedules. If given in a few (evensingle) 
fractions, but at a high fraction dose (stereotactic body 
radiotherapyor SBRT), RCC becomes highly radiosensitive. 
Both in the primary setting and intreatment of 
oligometastatic disease, local control rates >90% are 
achieved.There is an established biological rationale for the 
radiosensitivity ofrenal-cell carcinoma to SBRT which is based 
on the ceramide pathway, which isactivated only when a high 
dose per fraction is given. This pathway does notinvolve 
damage at the DNA level (nucleus) but at the level of the 
cellmembrane. The ultimate target of this pathway is the 
tumour vasculature,similar to lots of targeted drugs. 
Apartfrom the direct effect of SBRT on renal-cell carcinoma, 
stereotactic bodyradiotherapy can also induce an abscopal 
effect. This effect, caused byimmunological processes and 
involving dendritic cells, might be enhanced whentargeted 
drugs and stereotactic body radiotherapy are combined. 
Therefore,rigorous, prospective randomized trials involving a 
multidisciplinaryscientific panel are needed urgently. The 
presence of a radiation oncologist insuch panels is vital. 
Thisoral presentation will focus on: 
1. Radiobiologyof SBRT in RCC (ceramide pathway). 
2. Rationalefor the abscopal effect. 
3. Localcontrol rates of SBRT in RCC. 
4. Interactionbetween targeted drugs and SBRT. 
5. Increasingvisibility if radiation oncology in this setting. 
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There has been an increase in incidence of small renal masses 
over the last two decades. There is evidence that nephron 
sparing surgery offers equivalent long-term oncological 
results compared to radical nephrectomy. More recent 
evidence suggests that radical nephrectomy is associated 
with greater chronic renal insufficiency, which is in turn 
associated with increased risk of cardiovascular death, in 
patients with localised T1 renal mass. It is for these reasons 
that nephron sparing surgery is recommended, when 
technically feasible, for the management of renal tumour 
smaller than 7 cm.  
Partial nephrectomy is the gold standard treatment for small 
renal masses, however it is associated with a significant 
morbidity.  
Ablative treatments are alternative options that cause 
necrosis of the renal tumour without removing it. This can be 
achieved by heating tumour up to 80°C, with radiofrequency, 
or by freezing it below -40°C with cryosurgery. These 
percutaneous ablative treatments are performed under CT 
scan guidance or by laparoscopic approach. The percutaneous 
approach can be performed under local anaesthesia, which is 
particularly useful in fragile patients. These two minimally 
invasive ablative treatments allow, on average, to halve the 
postoperative morbidity when compared to partial 
nephrectomy. On the other hand, the risk of local recurrence 
is higher compared to partial nephrectomy. 
Cancer specific survival rate on literature review is quoted 
around 90 to 95% for T1a (<4 cm) tumours. The 5 years 
overall survival or metastatic free survival, don’t seem to be 
different from partial nephrectomy, if salvage treatments are 
proposed in case of local recurrence. To achieve these 
oncological results, appropriate patient selection along with 
adequate follow up is required.  
According to the various urological guidelines, renal biopsy 
must be performed prior to these ablative treatments. When 
a malignant tumour is confirmed histologically, these 
treatments are recommended for cortical tumours, smaller 
than 4 cm, ideally in elderly patients or patients with 
multiple comorbidities who have a reasonable life 
expectancy. Patients with bilateral synchronous tumours, 
genetic diseases leading to multiple bilateral recurrences, 
renal insufficiency or presence of solitary kidney, are also 
ideal candidates for ablative treatments. Patients with 
shorter life expectancy, tumours in the hilum or in close 
proximity to the collecting system and proximal ureter are 
contraindications. Cryosurgery appears to treat central 
tumours with less morbidity compared to radiofrequency 
ablation. Close radiological follow up is required. Renal CT 
scan or MRI is usually performed at regular intervals looking 
for any possible enhancement of recurrent/residual tumour.  
Conclusion: Partial nephrectomy remains the gold standard 
treatment for management of small renal tumours. Ablative 
treatment is a validated option associated with a favourable 
risk benefit balance, especially for fragile patients.  
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The practice of brachytherapy nowadays has been developed 
decennia ago. In the course of years modifications are 
introduced by the use of different isotopes, the development 
of afterloading techniques, the introduction of image-guided 
techniques, and many more. Robotics technologies are on a 
wide scale increasingly being used in the treatment of 
patients. Also in brachytherapy this emerging technology has 
been adopted and is still in development. A robot is a 
